Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Teru Hideshima
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Chemicals & Drugs
Anatomy
Physiology
Living Beings
Phenomena
Sign-in to see full Profile
Network (preview)
205
Anderson, Kenneth
132
Chauhan, Dharminder
92
Munshi, Nikhil
73
podar, klaus
71
Mitsiades, Constantine
60
Raje, Noopur
58
Tai, Yu-Tzu
53
Richardson, Paul
52
Richardson, Paul
38
Mitsiades, Nicholas
35
Schlossman, Robert
31
Catley, Laurence
29
Treon, Steve
28
Yasui, Hiroshi
26
Ishitsuka, Kenji
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Teru Hideshima (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Negri Joseph M; McMillin Douglas W; Delmore Jake; Mitsiades Nicholas; Hayden Patrick; Klippel Steffen; Hideshima Teru; Chauhan Dharminder; Munshi Nikhil C; Buser Carolyn A; Pollard John; Richardson Paul G; Anderson Kenneth C; Mitsiades Constantine S
In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.
British journal of haematology 2009;147(5):672-6.
-
2009: Laubach Jacob P; Mitsiades Constantine S; Mahindra Anuj; Schlossman Robert L; Hideshima Teru; Chauhan Dharminder; Carreau Nicole A; Ghobrial Irene M; Raje Noopur; Munshi Nikhil C; Anderson Kenneth C; Richardson Paul G
Novel therapies in the treatment of multiple myeloma.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(9):947-60.
-
2009: Chauhan Dharminder; Singh Ajita V; Brahmandam Mohan; Carrasco Ruben; Bandi Madhavi; Hideshima Teru; Bianchi Giada; Podar Klaus; Tai Yu-Tzu; Mitsiades Constantine; Raje Noopur; Jaye David L; Kumar Shaji K; Richardson Paul; Munshi Nikhil; Anderson Kenneth C
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.
Cancer cell 2009;16(4):309-23.
-
2009: Pozzi Samantha; Vallet Sonia; Mukherjee Siddhartha; Cirstea Diana; Vaghela Nileshwari; Santo Loredana; Rosen Eyal; Ikeda Hiroshi; Okawa Yutaka; Kiziltepe Tanyel; Schoonmaker Jesse; Xie Wanling; Hideshima Teru; Weller Edie; Bouxsein Mary L; Munshi Nikhil C; Anderson Kenneth C; Raje Noopur
High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(18):5829-39.
-
2009: Dutta-Simmons Jui; Zhang Yunyu; Gorgun Gullu; Gatt Moshe; Mani Mala; Hideshima Teru; Takada Kohichi; Carlson Nicole E; Carrasco Daniel E; Tai Yu-Tzu; Raje Noopur; Letai Anthony G; Anderson Kenneth C; Carrasco Daniel R
Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression.
Blood 2009;114(13):2699-708.
-
2009: Hideshima Teru; Ikeda Hiroshi; Chauhan Dharminder; Okawa Yutaka; Raje Noopur; Podar Klaus; Mitsiades Constantine; Munshi Nikhil C; Richardson Paul G; Carrasco Ruben D; Anderson Kenneth C
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
Blood 2009;114(5):1046-52.
-
2009: Fulciniti Mariateresa; Tassone Pierfrancesco; Hideshima Teru; Vallet Sonia; Nanjappa Puru; Ettenberg Seth A; Shen Zhenxin; Patel Nipun; Tai Yu-Tzu; Chauhan Dharminder; Mitsiades Constantine; Prabhala Rao; Raje Noopur; Anderson Kenneth C; Stover David R; Munshi Nikhil C
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.
Blood 2009;114(2):371-9.
-
2009: Zhang Jing; Sattler Martin; Tonon Giovanni; Grabher Clemens; Lababidi Samir; Zimmerhackl Alexander; Raab Marc S; Vallet Sonia; Zhou Yiming; Cartron Marie-Astrid; Hideshima Teru; Tai Yu-Tzu; Chauhan Dharminder; Anderson Kenneth C; Podar Klaus
Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma.
Cancer research 2009;69(12):5082-90.
-
2009: Ikeda Hiroshi; Hideshima Teru; Fulciniti Mariateresa; Lutz Robert J; Yasui Hiroshi; Okawa Yutaka; Kiziltepe Tanyel; Vallet Sonia; Pozzi Samantha; Santo Loredana; Perrone Giulia; Tai Yu-Tzu; Cirstea Diana; Raje Noopur S; Uherek Christoph; Dälken Benjamin; Aigner Silke; Osterroth Frank; Munshi Nikhil; Richardson Paul; Anderson Kenneth C
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(12):4028-37.
-
2009: Hideshima Teru; Chauhan Dharminder; Kiziltepe Tanyel; Ikeda Hiroshi; Okawa Yutaka; Podar Klaus; Raje Noopur; Protopopov Alexei; Munshi Nikhil C; Richardson Paul G; Carrasco Ruben D; Anderson Kenneth C
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.
Blood 2009;113(21):5228-36.
-
2009: Mitsiades Constantine S; Hideshima Teru; Chauhan Dharminder; McMillin Douglas W; Klippel Steffen; Laubach Jacob P; Munshi Nikhil C; Anderson Kenneth C; Richardson Paul G
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.
Seminars in hematology 2009;46(2):166-75.
-
2009: Tai Yu-Tzu; Soydan Ender; Song Weihua; Fulciniti Mariateresa; Kim Kihyun; Hong Fangxin; Li Xian-Feng; Burger Peter; Rumizen Matthew J; Nahar Sabikun; Podar Klaus; Hideshima Teru; Munshi Nikhil C; Tonon Giovanni; Carrasco Ruben D; Afar Daniel E H; Anderson Kenneth C
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.
Blood 2009;113(18):4309-18.
-
2009: Azab Abdel Kareem; Runnels Judith M; Pitsillides Costas; Moreau Anne-Sophie; Azab Feda; Leleu Xavier; Jia Xiaoying; Wright Renee; Ospina Beatriz; Carlson Alicia L; Alt Clemens; Burwick Nicholas; Roccaro Aldo M; Ngo Hai T; Farag Mena; Melhem Molly R; Sacco Antonio; Munshi Nikhil C; Hideshima Teru; Rollins Barrett J; Anderson Kenneth C; Kung Andrew L; Lin Charles P; Ghobrial Irene M
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
Blood 2009;113(18):4341-51.
-
2009: Podar Klaus; Tai Yu-Tzu; Hideshima Teru; Vallet Sonia; Richardson Paul G; Anderson Kenneth C
Emerging therapies for multiple myeloma.
Expert opinion on emerging drugs 2009;14(1):99-127.
-
2009: Raab Marc S; Breitkreutz Iris; Tonon Giovanni; Zhang Jing; Hayden Patrick J; Nguyen Thu; Fruehauf Johannes H; Lin Boris K; Chauhan Dharminder; Hideshima Teru; Munshi Nikhil C; Anderson Kenneth C; Podar Klaus
Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling.
Blood 2009;113(7):1513-21.
-
2009: Burger Renate; Le Gouill Steven; Tai Yu-Tzu; Shringarpure Reshma; Tassone Pierfrancesco; Neri Paola; Podar Klaus; Catley Laurence; Hideshima Teru; Chauhan Dharminder; Caulder Eian; Neilan Claire L; Vaddi Kris; Li Jun; Gramatzki Martin; Fridman Jordan S; Anderson Kenneth C
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.
Molecular cancer therapeutics 2009;8(1):26-35.
-
2009: Okawa Yutaka; Hideshima Teru; Steed Paul; Vallet Sonia; Hall Steven; Huang Ken; Rice John; Barabasz Amy; Foley Brianna; Ikeda Hiroshi; Raje Noopur; Kiziltepe Tanyel; Yasui Hiroshi; Enatsu Sotaro; Anderson Kenneth C
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.
Blood 2009;113(4):846-55.
-
2008: Nelson Erik A; Walker Sarah R; Kepich Alicia; Gashin Laurie B; Hideshima Teru; Ikeda Hiroshi; Chauhan Dharminder; Anderson Kenneth C; Frank David A
Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.
Blood 2008;112(13):5095-102.
-
2008: Tai Yu-Tzu; Dillon Myles; Song Weihua; Leiba Merav; Li Xian-Feng; Burger Peter; Lee Alfred I; Podar Klaus; Hideshima Teru; Rice Audie G; van Abbema Anne; Jesaitis Lynne; Caras Ingrid; Law Debbie; Weller Edie; Xie Wanling; Richardson Paul; Munshi Nikhil C; Mathiot Claire; Avet-Loiseau Hervé; Afar Daniel E H; Anderson Kenneth C
Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
Blood 2008;112(4):1329-37.
-
2008: Mitsiades Constantine S; Ocio Enrique M; Pandiella Atanasio; Maiso Patricia; Gajate Consuelo; Garayoa Mercedes; Vilanova David; Montero Juan Carlos; Mitsiades Nicholas; McMullan Ciaran J; Munshi Nikhil C; Hideshima Teru; Chauhan Dharminder; Aviles Pablo; Otero Gabriel; Faircloth Glynn; Mateos M Victoria; Richardson Paul G; Mollinedo Faustino; San-Miguel Jesus F; Anderson Kenneth C
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.
Cancer research 2008;68(13):5216-25.
-
2008: Richardson Paul G; Mitsiades Constantine; Schlossman Robert; Ghobrial Irene; Hideshima Teru; Munshi Nikhil; Anderson Kenneth C
Bortezomib in the front-line treatment of multiple myeloma.
Expert review of anticancer therapy 2008;8(7):1053-72.
-
2008: Okawa Yutaka; Hideshima Teru; Ikeda Hiroshi; Raje Noopur; Vallet Sonia; Kiziltepe Tanyel; Yasui Hiroshi; Enatsu Sotaro; Pozzi Samantha; Breitkreutz Iris; Cirstea Diana; Santo Loredana; Richardson Paul; Anderson Kenneth C
Fatty acid synthase is a novel therapeutic target in multiple myeloma.
British journal of haematology 2008;141(5):659-71.
-
2008: Ishitsuka Kenji; Hideshima Teru; Neri Paola; Vallet Sonia; Shiraishi Norihiko; Okawa Yutaka; Shen Zhenxin; Raje Noopur; Kiziltepe Tanyel; Ocio Enrique M; Chauhan Dharminder; Tassone Pierfrancesco; Munshi Nikhil; Campbell Robert M; Dios Alfonso De; Shih Chuan; Starling James J; Tamura Kazuo; Anderson Kenneth C
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.
British journal of haematology 2008;141(5):598-606.
-
2008: Leleu Xavier; Eeckhoute Jérôme; Jia Xiaoying; Roccaro Aldo M; Moreau Anne-Sophie; Farag Mena; Sacco Antonio; Ngo Hai T; Runnels Judith; Melhem Molly R; Burwick Nicolas; Azab Abdelkareem; Azab Feda; Hunter Zachary; Hatjiharissi Evdoxia; Carrasco Daniel R; Treon Steven P; Witzig Thomas E; Hideshima Teru; Brown Myles; Anderson Kenneth C; Ghobrial Irene M
Targeting NF-kappaB in Waldenstrom macroglobulinemia.
Blood 2008;111(10):5068-77.
-
2008: Roccaro Aldo M; Leleu Xavier; Sacco Antonio; Jia Xiaoying; Melhem Molly; Moreau Anne-Sophie; Ngo Hai T; Runnels Judith; Azab Abdelkareem; Azab Feda; Burwick Nicholas; Farag Mena; Treon Steven P; Palladino Michael A; Hideshima Teru; Chauhan Dharminder; Anderson Kenneth C; Ghobrial Irene M
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia.
Blood 2008;111(9):4752-63.
-
2008: Raje Noopur; Woo Sook-Bin; Hande Karen; Yap Jeffrey T; Richardson Paul G; Vallet Sonia; Treister Nathaniel; Hideshima Teru; Sheehy Niall; Chhetri Shweta; Connell Brendan; Xie Wanling; Tai Yu-Tzu; Szot-Barnes Agnieszka; Tian Mei; Schlossman Robert L; Weller Edie; Munshi Nikhil C; Van Den Abbeele Annick D; Anderson Kenneth C
Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(8):2387-95.
-
2008: Hideshima Teru; Raje Noopur; Richardson Paul G; Anderson Kenneth C
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma.
Therapeutics and clinical risk management 2008;4(1):129-36.
-
2008: Huston Alissa; Leleu Xavier; Jia Xiaoying; Moreau Anne-Sophie; Ngo Hai T; Runnels Judith; Anderson Judy; Alsayed Yazan; Roccaro Aldo; Vallet Sonia; Hatjiharissi Evdoxia; Tai Yu-Tsu; Sportelli Peter; Munshi Nikhil; Richardson Paul; Hideshima Teru; Roodman David G; Anderson Kenneth C; Ghobrial Irene M
Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(3):865-74.
-
2008: Mukherjee Siddhartha; Raje Noopur; Schoonmaker Jesse A; Liu Julie C; Hideshima Teru; Wein Marc N; Jones Dallas C; Vallet Sonia; Bouxsein Mary L; Pozzi Samantha; Chhetri Shweta; Seo Y David; Aronson Joshua P; Patel Chirayu; Fulciniti Mariateresa; Purton Louise E; Glimcher Laurie H; Lian Jane B; Stein Gary; Anderson Kenneth C; Scadden David T
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice.
The Journal of clinical investigation 2008;118(2):491-504.
-
2008: Chauhan Dharminder; Singh Ajita; Brahmandam Mohan; Podar Klaus; Hideshima Teru; Richardson Paul; Munshi Nikhil; Palladino Michael A; Anderson Kenneth C
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
Blood 2008;111(3):1654-64.
-
2008: Podar K; Gouill S L; Zhang J; Opferman J T; Zorn E; Tai Y-T; Hideshima T; Amiot M; Chauhan D; Harousseau J-L; Anderson K C
A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
Oncogene 2008;27(6):721-31.
-
2008: Chauhan Dharminder; Hideshima Teru; Anderson Kenneth C
Targeting proteasomes as therapy in multiple myeloma.
Advances in experimental medicine and biology 2008;615():251-60.
-
2007: Podar Klaus; Richardson Paul G; Hideshima Teru; Chauhan Dharminder; Anderson Kenneth C
The malignant clone and the bone-marrow environment.
Best practice & research. Clinical haematology 2007;20(4):597-612.
-
2007: Hideshima Teru; Anderson Kenneth C
Preclinical studies of novel targeted therapies.
Hematology/oncology clinics of North America 2007;21(6):1071-91, viii-ix.
-
2007: Mitsiades Constantine S; McMillin Douglas W; Klippel Steffen; Hideshima Teru; Chauhan Dharminder; Richardson Paul G; Munshi Nikhil C; Anderson Kenneth C
The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies.
Hematology/oncology clinics of North America 2007;21(6):1007-34, vii-viii.
-
2007: Neri P; Tassone P; Shammas M; Yasui H; Schipani E; Batchu R B; Blotta S; Prabhala R; Catley L; Hamasaki M; Hideshima T; Chauhan D; Jacob G S; Picker D; Venuta S; Anderson K C; Munshi N C
Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(12):2519-26.
-
2007: Leleu Xavier; Jia Xiaoying; Runnels Judith; Ngo Hai T; Moreau Anne-Sophie; Farag Mena; Spencer Joel A; Pitsillides Costas M; Hatjiharissi Evdoxia; Roccaro Aldo; O'Sullivan Garrett; McMillin Douglas W; Moreno Daisy; Kiziltepe Tanyel; Carrasco Ruben; Treon Steven P; Hideshima Teru; Anderson Kenneth C; Lin Charles P; Ghobrial Irene M
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.
Blood 2007;110(13):4417-26.
-
2007: Vallet Sonia; Raje Noopur; Ishitsuka Kenji; Hideshima Teru; Podar Klaus; Chhetri Shweta; Pozzi Samantha; Breitkreutz Iris; Kiziltepe Tanyel; Yasui Hiroshi; Ocio Enrique M; Shiraishi Norihiko; Jin Janice; Okawa Yutaka; Ikeda Hiroshi; Mukherjee Siddhartha; Vaghela Nileshwari; Cirstea Diana; Ladetto Marco; Boccadoro Mario; Anderson Kenneth C
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.
Blood 2007;110(10):3744-52.
-
2007: Neri Paola; Kumar Shaji; Fulciniti Maria Teresa; Vallet Sonia; Chhetri Shweta; Mukherjee Sidhartha; Tai Yutzu; Chauhan Dharminder; Tassone Pierfrancesco; Venuta Salvatore; Munshi Nikhil C; Hideshima Teru; Anderson Kenneth C; Raje Noopur
Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(19):5903-9.
-
2007: Breitkreutz Iris; Raab Marc S; Vallet Sonia; Hideshima Teru; Raje Noopur; Chauhan Dharminder; Munshi Nikhil C; Richardson Paul G; Anderson Kenneth C
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma.
British journal of haematology 2007;139(1):55-63.
-
2007: Hideshima Teru; Catley Laurence; Raje Noopur; Chauhan Dharminder; Podar Klaus; Mitsiades Constantine; Tai Yu-Tzu; Vallet Sonia; Kiziltepe Tanyel; Ocio Enrique; Ikeda Hiroshi; Okawa Yutaka; Hideshima Hiromasa; Munshi Nikhil C; Yasui Hiroshi; Richardson Paul G; Anderson Kenneth C
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
British journal of haematology 2007;138(6):783-91.
-
2007: Tai Yu-Tzu; Fulciniti Mariateresa; Hideshima Teru; Song Weihua; Leiba Merav; Li Xian-Feng; Rumizen Matthew; Burger Peter; Morrison Aileen; Podar Klaus; Chauhan Dharminder; Tassone Pierfrancesco; Richardson Paul; Munshi Nikhil C; Ghobrial Irene M; Anderson Kenneth C
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Blood 2007;110(5):1656-63.
-
2007: Hideshima Teru; Mitsiades Constantine; Tonon Giovanni; Richardson Paul G; Anderson Kenneth C
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.
Nature reviews. Cancer 2007;7(8):585-98.
-
2007: Younes Hashem; Leleu Xavier; Hatjiharissi Evdoxia; Moreau Anne-Sophie; Hideshima Teru; Richardson Paul; Anderson Kenneth C; Ghobrial Irene M
Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(13):3771-5.
-
2007: Catley Laurence; Hideshima Teru; Chauhan Dharminder; Neri Paola; Tassone Pierfrancesco; Bronson Roderick; Song Weihua; Tai Yu-Tzu; Munshi Nikhil C; Anderson Kenneth C
Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model.
Experimental hematology 2007;35(7):1038-46.
-
2007: Kiziltepe Tanyel; Hideshima Teru; Ishitsuka Kenji; Ocio Enrique M; Raje Noopur; Catley Laurence; Li Chun-Qi; Trudel Laura J; Yasui Hiroshi; Vallet Sonia; Kutok Jeffery L; Chauhan Dharminder; Mitsiades Constantine S; Saavedra Joseph E; Wogan Gerald N; Keefer Larry K; Shami Paul J; Anderson Kenneth C
JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.
Blood 2007;110(2):709-18.
-
2007: Ghobrial Joanne; Ghobrial Irene M; Mitsiades Constantine; Leleu Xavier; Hatjiharissi Evdoxia; Moreau Anne-Sophie; Roccaro Aldo; Schlossman Robert; Hideshima Teru; Anderson Kenneth C; Richardson Paul
Novel therapeutic avenues in myeloma: changing the treatment paradigm.
Oncology (Williston Park, N.Y.) 2007;21(7):785-92; discussion 798-800.
-
2007: Kiziltepe Tanyel; Hideshima Teru; Catley Laurence; Raje Noopur; Yasui Hiroshi; Shiraishi Norihiko; Okawa Yutaka; Ikeda Hiroshi; Vallet Sonia; Pozzi Samantha; Ishitsuka Kenji; Ocio Enrique M; Chauhan Dharminder; Anderson Kenneth C
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.
Molecular cancer therapeutics 2007;6(6):1718-27.
-
2007: Moreau Anne-Sophie; Jia Xiaoying; Ngo Hai T; Leleu Xavier; O'Sullivan Garrett; Alsayed Yazan; Leontovich Alexey; Podar Klaus; Kutok Jeffrey; Daley John; Lazo-Kallanian Suzan; Hatjiharissi Evdoxia; Raab Marc S; Xu Lian; Treon Steven P; Hideshima Teru; Anderson Kenneth C; Ghobrial Irene M
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.
Blood 2007;109(11):4964-72.
-
2007: Alsayed Yazan; Ngo Hai; Runnels Judith; Leleu Xavier; Singha Ujjal K; Pitsillides Costas M; Spencer Joel A; Kimlinger Teresa; Ghobrial Joanna M; Jia Xiaoying; Lu Ganwei; Timm Michael; Kumar Ashok; Côté Daniel; Veilleux Israel; Hedin Karen E; Roodman G David; Witzig Thomas E; Kung Andrew L; Hideshima Teru; Anderson Kenneth C; Lin Charles P; Ghobrial Irene M
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.
Blood 2007;109(7):2708-17.
-
2007: Chauhan D; Velankar M; Brahmandam M; Hideshima T; Podar K; Richardson P; Schlossman R; Ghobrial I; Raje N; Munshi N; Anderson K C
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
Oncogene 2007;26(16):2374-80.
-
2007: Ghobrial Irene M; Leleu Xavier; Hatjiharissi Evdoxia; Hideshima Teru; Mitsiades Constantine; Schlossman Robert; Anderson Kenneth C; Richardson Paul
Emerging drugs in multiple myeloma.
Expert opinion on emerging drugs 2007;12(1):155-63.
-
2007: Yasui H; Hideshima T; Ikeda H; Ocio E M; Kiziltepe T; Vallet S; Okawa Y; Neri P; Sukhdeo K; Podar K; Chauhan D; Richardson P G; Raje N; Carrasco D R; Anderson K C
Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(3):535-40.
-
2007: Richardson Paul G; Hideshima Teru; Mitsiades Constantine; Anderson Kenneth C
The emerging role of novel therapies for the treatment of relapsed myeloma.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(2):149-62.
-
2007: Podar Klaus; Raab Marc S; Tonon Giovanni; Sattler Martin; Barilà Daniela; Zhang Jing; Tai Yu-Tzu; Yasui Hiroshi; Raje Noopur; DePinho Ronald A; Hideshima Teru; Chauhan Dharminder; Anderson Kenneth C
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.
Cancer research 2007;67(4):1680-8.
-
2007: Yasui Hiroshi; Hideshima Teru; Ikeda Hiroshi; Jin Janice; Ocio Enrique M; Kiziltepe Tanyel; Okawa Yutaka; Vallet Sonia; Podar Klaus; Ishitsuka Kenji; Richardson Paul G; Pargellis Chris; Moss Neil; Raje Noopur; Anderson Kenneth C
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
British journal of haematology 2007;136(3):414-23.
-
2007: Chauhan Dharminder; Neri Paola; Velankar Mugdha; Podar Klaus; Hideshima Teru; Fulciniti Mariateresa; Tassone Pierfrancesco; Raje Noopur; Mitsiades Constantine; Mitsiades Nicholas; Richardson Paul; Zawel Leigh; Tran Mary; Munshi Nikhil; Anderson Kenneth C
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).
Blood 2007;109(3):1220-7.
-
2007: Podar Klaus; Raab Marc S; Zhang Jing; McMillin Douglas; Breitkreutz Iris; Tai Yu-Tzu; Lin Boris K; Munshi Nikhil; Hideshima Teru; Chauhan Dharminder; Anderson Kenneth C
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).
Blood 2007;109(4):1669-77.
-
2007: Richardson Paul; Mitsiades Constantine; Schlossman Robert; Ghobrial Irene; Hideshima Teru; Chauhan Dharminder; Munshi Nikhil; Anderson Kenneth
The treatment of relapsed and refractory multiple myeloma.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2007;():317-23.
-
2006: Yasui Hiroshi; Hideshima Teru; Anderson Kenneth C
Non-steroidal anti-inflammatory drug therapy for chronic lymphocytic leukemia.
Leukemia & lymphoma 2006;47(12):2445-6.
-
2006: Podar Klaus; Tonon Giovanni; Sattler Martin; Tai Yu-Tzu; Legouill Steven; Yasui Hiroshi; Ishitsuka Kenji; Kumar Shaji; Kumar Rakesh; Pandite Lini N; Hideshima Teru; Chauhan Dharminder; Anderson Kenneth C
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(51):19478-83.
-
2006: Francis Lanie K; Alsayed Yazan; Leleu Xavier; Jia Xiaoying; Singha Ujjal K; Anderson Judith; Timm Michael; Ngo Hai; Lu Ganwei; Huston Alissa; Ehrlich Lori A; Dimmock Elizabeth; Lentzsch Suzanne; Hideshima Teru; Roodman G David; Anderson Kenneth C; Ghobrial Irene M
Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(22):6826-35.
-
2006: Richardson Paul G; Blood Emily; Mitsiades Constantine S; Jagannath Sundar; Zeldenrust Steven R; Alsina Melissa; Schlossman Robert L; Rajkumar S Vincent; Desikan K Raman; Hideshima Teru; Munshi Nikhil C; Kelly-Colson Kathleen; Doss Deborah; McKenney Mary L; Gorelik Svetlana; Warren Diane; Freeman Andrea; Rich Rebecca; Wu Anfang; Olesnyckyj Marta; Wride Kenton; Dalton William S; Zeldis Jerome; Knight Robert; Weller Edie; Anderson Kenneth C
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Blood 2006;108(10):3458-64.
-
2006: Catley Laurence; Weisberg Ellen; Kiziltepe Tanyel; Tai Yu-Tzu; Hideshima Teru; Neri Paola; Tassone Pierfrancesco; Atadja Peter; Chauhan Dharminder; Munshi Nikhil C; Anderson Kenneth C
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
Blood 2006;108(10):3441-9.
-
2006: Yasui Hiroshi; Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Recent advances in the treatment of Multiple Myeloma.
Current pharmaceutical biotechnology 2006;7(5):381-93.
-
2006: Mitsiades Constantine S; Mitsiades Nicholas; Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Proteasome inhibition as a new therapeutic principle in hematological malignancies.
Current drug targets 2006;7(10):1341-7.
-
2006: Chauhan D; Hideshima T; Anderson K C
A novel proteasome inhibitor NPI-0052 as an anticancer therapy.
British journal of cancer 2006;95(8):961-5.
-
2006: Hideshima Teru; Neri Paola; Tassone Pierfranchesco; Yasui Hiroshi; Ishitsuka Kenji; Raje Noopur; Chauhan Dharminder; Podar Klaus; Mitsiades Constantine; Dang Lenny; Munshi Nikhil; Richardson Paul; Schenkein David; Anderson Kenneth C
MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5887-94.
-
2006: Raje N; Kumar S; Hideshima T; Ishitsuka K; Yasui H; Chhetri S; Vallet S; Vonescu E; Shiraishi N; Kiziltepe T; Elford H L; Munshi N C; Anderson K C
Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells.
British journal of haematology 2006;135(1):52-61.
-
2006: Raje Noopur; Hideshima Teru; Anderson Kenneth C
Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
Expert review of anticancer therapy 2006;6(9):1239-47.
-
2006: Richardson Paul G; Mitsiades Constantine; Hideshima Teru; Anderson Kenneth C
Lenalidomide in multiple myeloma.
Expert review of anticancer therapy 2006;6(8):1165-73.
-
2006: Yasui Hiroshi; Hideshima Teru
[Proteasome inhibitor bortezomib as an anticancer drug]
Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme 2006;51(10 Suppl):1251-6.
-
2006: Shringarpure Reshma; Catley Laurence; Bhole Deepak; Burger Renate; Podar Klaus; Tai Yu-Tzu; Kessler Benedikt; Galardy Paul; Ploegh Hidde; Tassone Pierfrancesco; Hideshima Teru; Mitsiades Constantine; Munshi Nikhil C; Chauhan Dharminder; Anderson Kenneth C
Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
British journal of haematology 2006;134(2):145-56.
-
2006: Tai Yu-Tzu; Li Xian-Feng; Breitkreutz Iris; Song Weihua; Neri Paola; Catley Laurence; Podar Klaus; Hideshima Teru; Chauhan Dharminder; Raje Noopur; Schlossman Robert; Richardson Paul; Munshi Nikhil C; Anderson Kenneth C
Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Cancer research 2006;66(13):6675-82.
-
2006: Neri Paola; Yasui Hiroshi; Hideshima Teru; Tassone Pierfrancesco; Raje Noopur; Catley Laurence P; Ishitsuka Kenji; Blotta Simona; Kiziltepe Tanyel; Ocio Enrique M; Fulciniti Mariateresa; Kanekal Sarath; Elliott Gary T; Munshi Nikhil C; Anderson Kenneth C
In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.
British journal of haematology 2006;134(1):37-44.
-
2006: Navas T A; Nguyen A N; Hideshima T; Reddy M; Ma J Y; Haghnazari E; Henson M; Stebbins E G; Kerr I; O'Young G; Kapoun A M; Chakravarty S; Mavunkel B; Perumattam J; Luedtke G; Dugar S; Medicherla S; Protter A A; Schreiner G F; Anderson K C; Higgins L S
Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2006;20(6):1017-27.
-
2006: Hideshima Teru; Catley Laurence; Yasui Hiroshi; Ishitsuka Kenji; Raje Noopur; Mitsiades Constantine; Podar Klaus; Munshi Nikhil C; Chauhan Dharminder; Richardson Paul G; Anderson Kenneth C
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
Blood 2006;107(10):4053-62.
-
2006: Kumar Shaji; Raje Noopur; Hideshima Teru; Ishitsuka Kenji; Podar Klaus; Le Gouille Steven; Chauhan Dharminder; Richardson Paul; Munshi Nikhil C; Anderson Kenneth
FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma.
British journal of haematology 2006;132(6):698-704.
-
2006: Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Current therapeutic uses of lenalidomide in multiple myeloma.
Expert opinion on investigational drugs 2006;15(2):171-9.
-
2006: Yasui Hiroshi; Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma.
British journal of haematology 2006;132(4):385-97.
-
2006: Mitsiades Constantine S; Mitsiades Nicholas S; McMullan Ciaran J; Poulaki Vassiliki; Kung Andrew L; Davies Faith E; Morgan Gareth; Akiyama Masaharu; Shringarpure Reshma; Munshi Nikhil C; Richardson Paul G; Hideshima Teru; Chauhan Dharminder; Gu Xuesong; Bailey Charles; Joseph Marie; Libermann Towia A; Rosen Neal S; Anderson Kenneth C
Antimyeloma activity of heat shock protein-90 inhibition.
Blood 2006;107(3):1092-100.
-
2006: Roccaro Aldo Maria; Hideshima Teru; Raje Noopur; Kumar Shaji; Ishitsuka Kenji; Yasui Hiroshi; Shiraishi Norihiko; Ribatti Domenico; Nico Beatrice; Vacca Angelo; Dammacco Franco; Richardson Paul Gerard; Anderson Kenneth Carl
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Cancer research 2006;66(1):184-91.
-
2006: Richardson Paul G; Mitsiades Constantine; Hideshima Teru; Anderson Kenneth C
Bortezomib: proteasome inhibition as an effective anticancer therapy.
Annual review of medicine 2006;57():33-47.
-
2005: Richardson Paul G; Schlossman Robert; Hideshima Teru; Anderson Kenneth C
New treatments for multiple myeloma.
Oncology (Williston Park, N.Y.) 2005;19(14):1781-92; discussion 1792, 1795-7.
-
2005: Hideshima Teru; Bradner James E; Chauhan Dharminder; Anderson Kenneth C
Intracellular protein degradation and its therapeutic implications.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(24 Pt 1):8530-3.
-
2005: Tai Yu-Tzu; Li Xian-Feng; Catley Laurence; Coffey Rory; Breitkreutz Iris; Bae Jooeun; Song Weihua; Podar Klaus; Hideshima Teru; Chauhan Dharminder; Schlossman Robert; Richardson Paul; Treon Steven P; Grewal Iqbal S; Munshi Nikhil C; Anderson Kenneth C
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
Cancer research 2005;65(24):11712-20.
-
2005: Chauhan Dharminder; Catley Laurence; Li Guilan; Podar Klaus; Hideshima Teru; Velankar Mugdha; Mitsiades Constantine; Mitsiades Nicolas; Yasui Hiroshi; Letai Anthony; Ovaa Huib; Berkers Celia; Nicholson Benjamin; Chao Ta-Hsiang; Neuteboom Saskia T C; Richardson Paul; Palladino Michael A; Anderson Kenneth C
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
Cancer cell 2005;8(5):407-19.
-
2005: Richardson Paul Gerard Guy; Barlogie Bart; Berenson James; Singhal Seema; Jagannath Sundar; Irwin David; Rajkumar S Vincent; Hideshima Teru; Xiao Hugh; Esseltine Dixie; Schenkein David; Anderson Kenneth C;
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.
Blood 2005;106(9):2977-81.
-
2005: Richardson Paul G; Schlossman Robert; Mitsiades Constantine; Hideshima Teru; Munshi Nikhil; Anderson Kenneth
Emerging trends in the clinical use of bortezomib in multiple myeloma.
Clinical lymphoma & myeloma 2005;6(2):84-8.
-
2005: Chauhan Dharminder; Li Guilan; Podar Klaus; Hideshima Teru; Neri Paola; He Deli; Mitsiades Nicholas; Richardson Paul; Chang Yan; Schindler Joanne; Carver Bradley; Anderson Kenneth C
A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Cancer research 2005;65(18):8350-8.
-
2005: Hideshima Teru; Chauhan Dharminder; Richardson Paul; Anderson Kenneth C
Identification and validation of novel therapeutic targets for multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(26):6345-50.
-
2005: Altun Mikael; Galardy Paul J; Shringarpure Reshma; Hideshima Teru; LeBlanc Richard; Anderson Kenneth C; Ploegh Hidde L; Kessler Benedikt M
Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.
Cancer research 2005;65(17):7896-901.
-
2005: Ishitsuka Kenji; Hideshima Teru; Hamasaki Makoto; Raje Noopur; Kumar Shaji; Podar Klaus; Le Gouill Steven; Shiraishi Norihiko; Yasui Hiroshi; Roccaro Aldo M; Tai Yu-Zu; Chauhan Dharminder; Fram Robert; Tamura Kazuo; Jain Jugnu; Anderson Kenneth C
Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway.
Oncogene 2005;24(38):5888-96.
-
2005: Ishitsuka Kenji; Hideshima Teru; Hamasaki Makoto; Raje Noopur; Kumar Shaji; Hideshima Hiromasa; Shiraishi Norihiko; Yasui Hiroshi; Roccaro Aldo M; Richardson Paul; Podar Klaus; Le Gouill Steven; Chauhan Dharminder; Tamura Kazuo; Arbiser Jack; Anderson Kenneth C
Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis.
Blood 2005;106(5):1794-800.
-
2005: Yasui Hiroshi; Hideshima Teru; Raje Noopur; Roccaro Aldo M; Shiraishi Norihiko; Kumar Shaji; Hamasaki Makoto; Ishitsuka Kenji; Tai Yu-Tzu; Podar Klaus; Catley Laurence; Mitsiades Constantine S; Richardson Paul G; Albert Rainer; Brinkmann Volker; Chauhan Dharminder; Anderson Kenneth C
FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Cancer research 2005;65(16):7478-84.
-
2005: Raje Noopur; Kumar Shaji; Hideshima Teru; Roccaro Aldo; Ishitsuka Kenji; Yasui Hiroshi; Shiraishi Norihiko; Chauhan Dharminder; Munshi Nikhil C; Green Simon R; Anderson Kenneth C
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
Blood 2005;106(3):1042-7.
-
2005: Tai Yu-Tzu; Li Xianfeng; Tong Xia; Santos Daniel; Otsuki Takemi; Catley Laurence; Tournilhac Olivier; Podar Klaus; Hideshima Teru; Schlossman Robert; Richardson Paul; Munshi Nikhil C; Luqman Mohammad; Anderson Kenneth C
Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.
Cancer research 2005;65(13):5898-906.
-
2005: Kumar S; Raje N; Hideshima T; Ishitsuka K; Roccaro A; Shiraishi N; Hamasaki M; Yasui H; Munshi N C; Richardson P; Figg W D; Anderson K C
Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(7):1253-61.
-
2005: Yasui Hiroshi; Hideshima Teru; Hamasaki Makoto; Roccaro Aldo M; Shiraishi Norihiko; Kumar Shaji; Tassone Pierfrancesco; Ishitsuka Kenji; Raje Noopur; Tai Yu-Tzu; Podar Klaus; Chauhan Dharminder; Leoni Lorenzo M; Kanekal Sarath; Elliott Gary; Munshi Nikhil C; Anderson Kenneth C
SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.
Blood 2005;106(2):706-12.
-
2005: Mitsiades Constantine S; Mitsiades Nicholas; Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
Expert review of anticancer therapy 2005;5(3):465-76.
-
2005: Hideshima Teru; Bradner James E; Wong Jason; Chauhan Dharminder; Richardson Paul; Schreiber Stuart L; Anderson Kenneth C
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(24):8567-72.
-
2005: Hamasaki Makoto; Hideshima Teru; Tassone Pierfrancesco; Neri Paola; Ishitsuka Kenji; Yasui Hiroshi; Shiraishi Norihiko; Raje Noopur; Kumar Shaji; Picker Donald H; Jacob Gary S; Richardson Paul G; Munshi Nikhil C; Anderson Kenneth C
Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.
Blood 2005;105(11):4470-6.
-
2005: Podar Klaus; Hideshima Teru; Chauhan Dharminder; Anderson Kenneth C
Targeting signalling pathways for the treatment of multiple myeloma.
Expert opinion on therapeutic targets 2005;9(2):359-81.
-
2005: Chauhan Dharminder; Hideshima Teru; Mitsiades Constantine; Richardson Paul; Anderson Kenneth C
Proteasome inhibitor therapy in multiple myeloma.
Molecular cancer therapeutics 2005;4(4):686-92.
-
2005: Hideshima Teru; Chauhan Dharminder; Ishitsuka Kenji; Yasui Hiroshi; Raje Noopur; Kumar Shaji; Podar Klaus; Mitsiades Constantine; Hideshima Hiromasa; Bonham Lynn; Munshi Nikhil C; Richardson Paul G; Singer Jack W; Anderson Kenneth C
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.
Oncogene 2005;24(19):3121-9.
-
2005: Richardson Paul G; Mitsiades Constantine; Hideshima Teru; Anderson Kenneth C
Proteasome inhibition in the treatment of cancer.
Cell cycle (Georgetown, Tex.) 2005;4(2):290-6.
-
2005: Rajkumar S Vincent; Richardson Paul G; Hideshima Teru; Anderson Kenneth C
Proteasome inhibition as a novel therapeutic target in human cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(3):630-9.
-
2005: Hayashi Toshiaki; Hideshima Teru; Akiyama Masaharu; Podar Klaus; Yasui Hiroshi; Raje Noopur; Kumar Shaji; Chauhan Dharminder; Treon Steven P; Richardson Paul; Anderson Kenneth C
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.
British journal of haematology 2005;128(2):192-203.
-
2005: Mitsiades Constantine S; Mitsiades Nicholas; Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Proteasome inhibitors as therapeutics.
Essays in biochemistry 2005;41():205-18.
-
2005: Richardson Paul G; Mitsiades Constantine S; Hideshima Teru; Anderson Kenneth C
Novel biological therapies for the treatment of multiple myeloma.
Best practice & research. Clinical haematology 2005;18(4):619-34.
-
2005: Hideshima Teru; Podar Klaus; Chauhan Dharminder; Anderson Kenneth C
Cytokines and signal transduction.
Best practice & research. Clinical haematology 2005;18(4):509-24.
-
2005: Chauhan Dharminder; Hideshima Teru; Anderson Kenneth C
Proteasome inhibition in multiple myeloma: therapeutic implication.
Annual review of pharmacology and toxicology 2005;45():465-76.
-
2004: Catley Laurence; Tai Yu-Tzu; Shringarpure Reshma; Burger Renate; Son Moni Thi; Podar Klaus; Tassone Pierfrancesco; Chauhan Dharminder; Hideshima Teru; Denis Louis; Richardson Paul; Munshi Nikhil C; Anderson Kenneth C
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Cancer research 2004;64(23):8746-53.
-
2004: Raje Noopur; Kumar Shaji; Hideshima Teru; Ishitsuka Kenji; Chauhan Dharminder; Mitsiades Constantine; Podar Klaus; Le Gouill Steven; Richardson Paul; Munshi Nikhil C; Stirling David I; Antin Joseph H; Anderson Kenneth C
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.
Blood 2004;104(13):4188-93.
-
2004: Tassone Pierfrancesco; Goldmacher Victor S; Neri Paola; Gozzini Antonella; Shammas Masood A; Whiteman Kathleen R; Hylander-Gans Linda L; Carrasco Daniel R; Hideshima Teru; Shringarpure Reshma; Shi Jialan; Allam Charles K; Wijdenes John; Venuta Salvatore; Munshi Nikhil C; Anderson Kenneth C
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.
Blood 2004;104(12):3688-96.
-
2004: Hayashi Toshiaki; Hideshima Teru; Nguyen Aaron N; Munoz Olivier; Podar Klaus; Hamasaki Makoto; Ishitsuka Kenji; Yasui Hiroshi; Richardson Paul; Chakravarty Sarvajit; Murphy Alison; Chauhan Dharminder; Higgins Linda S; Anderson Kenneth C
Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(22):7540-6.
-
2004: Hideshima Teru; Podar Klaus; Chauhan Dharminder; Ishitsuka Kenji; Mitsiades Constantine; Tai Yu-Tzu; Hamasaki Makoto; Raje Noopur; Hideshima Hiromasa; Schreiner George; Nguyen Aaron N; Navas Tony; Munshi Nikhil C; Richardson Paul G; Higgins Linda S; Anderson Kenneth C
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
Oncogene 2004;23(54):8766-76.
-
2004: Le Gouill Steven; Podar Klaus; Amiot Martine; Hideshima Teru; Chauhan Dharminder; Ishitsuka Kenji; Kumar Shaji; Raje Noopur; Richardson Paul G; Harousseau Jean-Luc; Anderson Kenneth C
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis.
Blood 2004;104(9):2886-92.
-
2004: Podar Klaus; Shringarpure Reshma; Tai Yu-Tzu; Simoncini Melissa; Sattler Martin; Ishitsuka Kenji; Richardson Paul G; Hideshima Teru; Chauhan Dharminder; Anderson Kenneth C
Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.
Cancer research 2004;64(20):7500-6.
-
2004: Chauhan Dharminder; Li Guilan; Podar Klaus; Hideshima Teru; Mitsiades Constantine; Schlossman Robert; Munshi Nikhil; Richardson Paul; Cotter Finbarr E; Anderson Kenneth C
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
Blood 2004;104(8):2458-66.
-
2004: Hideshima Teru; Bergsagel P Leif; Kuehl W Michael; Anderson Kenneth C
Advances in biology of multiple myeloma: clinical applications.
Blood 2004;104(3):607-18.
-
2004: Richardson Paul; Schlossman Robert; Jagannath Sundar; Alsina Melissa; Desikan Raman; Blood Emily; Weller Edie; Mitsiades Constantine; Hideshima Teru; Davies Faith; Doss Deborah; Freeman Andrea; Bosch Joan; Patin John; Knight Robert; Zeldis Jerome; Dalton William; Anderson Kenneth
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
Mayo Clinic proceedings. Mayo Clinic 2004;79(7):875-82.
-
2004: Richardson Paul; Hideshima Teru; Anderson Kenneth C
An update of novel therapeutic approaches for multiple myeloma.
Current treatment options in oncology 2004;5(3):227-38.
-
2004: Raje Noopur; Hideshima Teru; Davies Faith E; Chauhan Dharminder; Treon Steven P; Young Gloria; Tai Yu-Tzu; Avigan David; Gong Jianlin; Schlossman Robert L; Richardson Paul; Kufe Donald W; Anderson Kenneth C
Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.
British journal of haematology 2004;125(3):343-52.
-
2004: Podar Klaus; Mostoslavsky Gustavo; Sattler Martin; Tai Yu-Tzu; Hayashi Toshiaki; Catley Laurence P; Hideshima Teru; Mulligan Richard C; Chauhan Dharminder; Anderson Kenneth C
Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells.
The Journal of biological chemistry 2004;279(20):21658-65.
-
2004: Podar Klaus; Catley Laurence P; Tai Yu-Tzu; Shringarpure Reshma; Carvalho Pedro; Hayashi Toshiaki; Burger Renate; Schlossman Robert L; Richardson Paul G; Pandite Lini N; Kumar Rakesh; Hideshima Teru; Chauhan Dharminder; Anderson Kenneth C
GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Blood 2004;103(9):3474-9.
-
2004: Chauhan Dharminder; Li Guilan; Hideshima Teru; Podar Klaus; Shringarpure Reshma; Mitsiades Constantine; Munshi Nikhil; Yew P Renee; Anderson Kenneth C
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341.
Oncogene 2004;23(20):3597-602.
-
2004: Tai Yu-Tzu; Catley Laurence P; Mitsiades Constantine S; Burger Renate; Podar Klaus; Shringpaure Reshma; Hideshima Teru; Chauhan Dharminder; Hamasaki Makoto; Ishitsuka Kenji; Richardson Paul; Treon Steven P; Munshi Nikhil C; Anderson Kenneth C
Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications.
Cancer research 2004;64(8):2846-52.
-
2004: Chauhan Dharminder; Li Guilan; Podar Klaus; Hideshima Teru; Shringarpure Reshma; Catley Laurence; Mitsiades Constantine; Munshi Nikhil; Tai Yu Tzu; Suh Nanjoo; Gribble Gordon W; Honda Tadashi; Schlossman Robert; Richardson Paul; Sporn Michael B; Anderson Kenneth C
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
Blood 2004;103(8):3158-66.
-
2004: Akiyama Masaharu; Yamada Osamu; Hideshima Teru; Yanagisawa Takaaki; Yokoi Kentaro; Fujisawa Kohji; Eto Yoshikatsu; Yamada Hisashi; Anderson Kenneth C
TNFalpha induces rapid activation and nuclear translocation of telomerase in human lymphocytes.
Biochemical and biophysical research communications 2004;316(2):528-32.
-
2004: Mitsiades Constantine S; Mitsiades Nicholas S; McMullan Ciaran J; Poulaki Vassiliki; Shringarpure Reshma; Akiyama Masaharu; Hideshima Teru; Chauhan Dharminder; Joseph Marie; Libermann Towia A; García-Echeverría Carlos; Pearson Mark A; Hofmann Francesco; Anderson Kenneth C; Kung Andrew L
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.
Cancer cell 2004;5(3):221-30.
-
2004: Chauhan D; Li G; Auclair D; Hideshima T; Podar K; Mitsiades N; Mitsiades C; Chen L B; Munshi N; Saxena S; Anderson K C
2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.
Apoptosis : an international journal on programmed cell death 2004;9(2):149-55.
-
2004: LeBlanc Richard; Hideshima Teru; Catley Laurence P; Shringarpure Reshma; Burger Renate; Mitsiades Nicholas; Mitsiades Constantine; Cheema Puneet; Chauhan Dharminder; Richardson Paul G; Anderson Kenneth C; Munshi Nikhil C
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.
Blood 2004;103(5):1787-90.
-
2004: Munshi Nikhil C; Hideshima Teru; Carrasco Daniel; Shammas Masood; Auclair Daniel; Davies Faith; Mitsiades Nicholas; Mitsiades Constantine; Kim Ryung Suk; Li Cheng; Rajkumar S Vincent; Fonseca Rafael; Bergsagel Lief; Chauhan Dharminder; Anderson Kenneth C
Identification of genes modulated in multiple myeloma using genetically identical twin samples.
Blood 2004;103(5):1799-806.
-
2004: Mitsiades Constantine S; Mitsiades Nicholas S; McMullan Ciaran J; Poulaki Vassiliki; Shringarpure Reshma; Hideshima Teru; Akiyama Masaharu; Chauhan Dharminder; Munshi Nikhil; Gu Xuesong; Bailey Charles; Joseph Marie; Libermann Towia A; Richon Victoria M; Marks Paul A; Anderson Kenneth C
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(2):540-5.
-
2004: Richardson Paul G; Hideshima Teru; Mitsiades Constantine; Anderson Kenneth
Proteasome inhibition in hematologic malignancies.
Annals of medicine 2004;36(4):304-14.
-
2003: Hideshima Teru; Chauhan Dharminder; Hayashi Toshiaki; Podar Klaus; Akiyama Masaharu; Mitsiades Constantine; MItsiades Nicholas; Gong Baoqing; Bonham Lynn; de Vries Peter; Munshi Nikhil; Richardson Paul G; Singer Jack W; Anderson Kenneth C
Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
Cancer research 2003;63(23):8428-36.
-
2003: Burger Renate; Bakker Frank; Guenther Andreas; Baum Wolfgang; Schmidt-Arras Dirk; Hideshima Teru; Tai Yu-Tzu; Shringarpure Reshma; Catley Laurence; Senaldi Giorgio; Gramatzki Martin; Anderson Kenneth C
Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival.
British journal of haematology 2003;123(5):869-78.
-
2003: Davies Faith E; Dring Ann M; Li Cheng; Rawstron Andrew C; Shammas Masood A; O'Connor Sheila M; Fenton James A L; Hideshima Teru; Chauhan Dharminder; Tai Isabella T; Robinson Elizabeth; Auclair Daniel; Rees Karen; Gonzalez David; Ashcroft A John; Dasgupta Ranjit; Mitsiades Constantine; Mitsiades Nicholas; Chen Lan B; Wong Wing H; Munshi Nikhil C; Morgan Gareth J; Anderson Kenneth C
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis.
Blood 2003;102(13):4504-11.
-
2003: Hideshima Teru; Hayashi Toshiaki; Chauhan Dharminder; Akiyama Masaharu; Richardson Paul; Anderson Kenneth
Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines.
Oncogene 2003;22(54):8797-801.
-
2003: Hideshima Teru; Chauhan Dharminder; Hayashi Toshiaki; Akiyama Masaharu; Mitsiades Nicholas; Mitsiades Constantine; Podar Klaus; Munshi Nikhil C; Richardson Paul G; Anderson Kenneth C
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.
Oncogene 2003;22(52):8386-93.
-
2003: Chauhan Dharminder; Li Guilan; Hideshima Teru; Podar Klaus; Mitsiades Constantine; Mitsiades Nicholas; Catley Laurence; Tai Yu Tzu; Hayashi Toshiaki; Shringarpure Reshma; Burger Renate; Munshi Nikhil; Ohtake Yasuyuki; Saxena Satya; Anderson Kenneth C
Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance.
Blood 2003;102(9):3379-86.
-
2003: Mitsiades Constantine S; Mitsiades Nicholas S; Bronson Ron T; Chauhan Dharminder; Munshi Nikhil; Treon Steven P; Maxwell Christopher A; Pilarski Linda; Hideshima Teru; Hoffman Robert M; Anderson Kenneth C
Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.
Cancer research 2003;63(20):6689-96.
-
2003: Akiyama Masaharu; Hideshima Teru; Shammas Masood A; Hayashi Toshiaki; Hamasaki Makoto; Tai Yu-Tzu; Richardson Paul; Gryaznov Sergei; Munshi Nikhil C; Anderson Kenneth C
Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells.
Cancer research 2003;63(19):6187-94.
-
2003: Chauhan Dharminder; Li Guilan; Shringarpure Reshma; Podar Klaus; Ohtake Yasuyuki; Hideshima Teru; Anderson Kenneth C
Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.
Cancer research 2003;63(19):6174-7.
-
2003: Catley Laurence; Weisberg Ellen; Tai Yu-Tzu; Atadja Peter; Remiszewski Stacy; Hideshima Teru; Mitsiades Nicholas; Shringarpure Reshma; LeBlanc Richard; Chauhan Dharminder; Munshi Nikhil C; Schlossman Robert; Richardson Paul; Griffin James; Anderson Kenneth C
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.
Blood 2003;102(7):2615-22.
-
2003: Richardson Paul G; Hideshima Teru; Anderson Kenneth C
Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.
Cancer control : journal of the Moffitt Cancer Center 2003;10(5):361-9.
-
2003: Shammas Masood A; Shmookler Reis Robert J; Akiyama Masaharu; Koley Hemanta; Chauhan Dharminder; Hideshima Teru; Goyal Raj K; Hurley Laurence H; Anderson Kenneth C; Munshi Nikhil C
Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.
Molecular cancer therapeutics 2003;2(9):825-33.
-
2003: Tai Yu-Tzu; Podar Klaus; Catley Laurence; Tseng Yu-Hua; Akiyama Masaharu; Shringarpure Reshma; Burger Renate; Hideshima Teru; Chauhan Dharminder; Mitsiades Nicholas; Richardson Paul; Munshi Nikhil C; Kahn C Ronald; Mitsiades Constantine; Anderson Kenneth C
Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.
Cancer research 2003;63(18):5850-8.
-
2003: Chauhan Dharminder; Li Guilan; Sattler Martin; Podar Klaus; Mitsiades Constantine; Mitsiades Nicholas; Munshi Nikhil; Hideshima Teru; Anderson Kenneth C
Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells.
Oncogene 2003;22(40):6296-300.
-
2003: Chauhan Dharminder; Hideshima Teru; Anderson Kenneth C
Apoptotic signaling in multiple myeloma: therapeutic implications.
International journal of hematology 2003;78(2):114-20.
-
2003: Hideshima Teru; Richardson Paul; Anderson Kenneth C
Novel therapeutic approaches for multiple myeloma.
Immunological reviews 2003;194():164-76.
-
2003: Hayashi Toshiaki; Hideshima Teru; Akiyama Masaharu; Raje Noopur; Richardson Paul; Chauhan Dharminder; Anderson Kenneth C
Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes.
Blood 2003;102(4):1435-42.
-
2003: Hideshima Teru; Richardson Paul G; Anderson Kenneth C
Targeting proteasome inhibition in hematologic malignancies.
Reviews in clinical and experimental hematology 2003;7(2):191-204.
-
2003: Richardson Paul G; Barlogie Bart; Berenson James; Singhal Seema; Jagannath Sundar; Irwin David; Rajkumar S Vincent; Srkalovic Gordan; Alsina Melissa; Alexanian Raymond; Siegel David; Orlowski Robert Z; Kuter David; Limentani Steven A; Lee Stephanie; Hideshima Teru; Esseltine Dixie-Lee; Kauffman Michael; Adams Julian; Schenkein David P; Anderson Kenneth C
A phase 2 study of bortezomib in relapsed, refractory myeloma.
The New England journal of medicine 2003;348(26):2609-17.
-
2003: Hayashi Toshiaki; Treon Steven P; Hideshima Teru; Tai Yu-Tzu; Akiyama Masaharu; Richardson Paul; Chauhan Dharminder; Grewal Iqbal S; Anderson Kenneth C
Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells.
British journal of haematology 2003;121(4):592-6.
-
2003: Chauhan Dharminder; Li Guilan; Hideshima Teru; Podar Klaus; Mitsiades Constantine; Mitsiades Nicholas; Munshi Nikhil; Kharbanda Surender; Anderson Kenneth C
JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells.
The Journal of biological chemistry 2003;278(20):17593-6.
-
2003: Mitsiades Nicholas; Mitsiades Constantine S; Richardson Paul G; McMullan Ciaran; Poulaki Vassiliki; Fanourakis Galinos; Schlossman Robert; Chauhan Dharminder; Munshi Nikhil C; Hideshima Teru; Richon Victoria M; Marks Paul A; Anderson Kenneth C
Molecular sequelae of histone deacetylase inhibition in human malignant B cells.
Blood 2003;101(10):4055-62.
-
2003: Chauhan Dharminder; Li Guilan; Auclair Daniel; Hideshima Teru; Richardson Paul; Podar Klaus; Mitsiades Nicholas; Mitsiades Constantine; Li Cheng; Kim Ryung Suk; Munshi Nikhil; Chen Lan Bo; Wong Wing; Anderson Kenneth C
Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays.
Blood 2003;101(9):3606-14.
-
2003: Greenstein Stephanie; Krett Nancy L; Kurosawa Yoshihiro; Ma Chunguang; Chauhan Dharminder; Hideshima Teru; Anderson Kenneth C; Rosen Steven T
Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells.
Experimental hematology 2003;31(4):271-82.
-
2003: Tai Yu-Tzu; Podar Klaus; Mitsiades Nicholas; Lin Boris; Mitsiades Constantine; Gupta Deepak; Akiyama Masaharu; Catley Laurence; Hideshima Teru; Munshi Nikhil C; Treon Steven P; Anderson Kenneth C
CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling.
Blood 2003;101(7):2762-9.
-
2003: Mitsiades Nicholas; Mitsiades Constantine S; Richardson Paul G; Poulaki Vassiliki; Tai Yu-Tzu; Chauhan Dharminder; Fanourakis Galinos; Gu Xuesong; Bailey Charles; Joseph Marie; Libermann Towia A; Schlossman Robert; Munshi Nikhil C; Hideshima Teru; Anderson Kenneth C
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
Blood 2003;101(6):2377-80.
-
2003: Podar Klaus; Tai Yu-Tzu; Cole Craig E; Hideshima Teru; Sattler Martin; Hamblin Angela; Mitsiades Nicholas; Schlossman Robert L; Davies Faith E; Morgan Gareth J; Munshi Nikhil C; Chauhan Dharminder; Anderson Kenneth C
Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells.
The Journal of biological chemistry 2003;278(8):5794-801.
-
2003: Hideshima Teru; Mitsiades Constantine; Akiyama Masaharu; Hayashi Toshiaki; Chauhan Dharminder; Richardson Paul; Schlossman Robert; Podar Klaus; Munshi Nikhil C; Mitsiades Nicholas; Anderson Kenneth C
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.
Blood 2003;101(4):1530-4.
-
2003: Lentzsch S; LeBlanc R; Podar K; Davies F; Lin B; Hideshima T; Catley L; Stirling D I; Anderson K C
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(1):41-4.
-
2003: Akiyama Masaharu; Hideshima Teru; Hayashi Toshiaki; Tai Yu-Tzu; Mitsiades Constantine S; Mitsiades Nicholas; Chauhan Dharminder; Richardson Paul; Munshi Nikhil C; Anderson Kenneth C
Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein.
Cancer research 2003;63(1):18-21.
-
2003: Hayashi Toshiaki; Hideshima Teru; Anderson Kenneth C
Novel therapies for multiple myeloma.
British journal of haematology 2003;120(1):10-7.
-
2003: Hideshima Teru; Akiyama Masaharu; Hayashi Toshiaki; Richardson Paul; Schlossman Robert; Chauhan Dharminder; Anderson Kenneth C
Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu.
Blood 2003;101(2):703-5.
-
2002: Hideshima Teru; Anderson Kenneth C
Molecular mechanisms of novel therapeutic approaches for multiple myeloma.
Nature reviews. Cancer 2002;2(12):927-37.
-
2002: Richardson Paul G; Schlossman Robert L; Weller Edie; Hideshima Teru; Mitsiades Constantine; Davies Faith; LeBlanc Richard; Catley Laurence P; Doss Deborah; Kelly Kathleen; McKenney Mary; Mechlowicz Julie; Freeman Andrea; Deocampo Reggie; Rich Rebecca; Ryoo Joan J; Chauhan Dharminder; Balinski Kathe; Zeldis Jerome; Anderson Kenneth C
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Blood 2002;100(9):3063-7.
-
2002: Mitsiades Nicholas; Mitsiades Constantine S; Poulaki Vassiliki; Chauhan Dharminder; Fanourakis Galinos; Gu Xuesong; Bailey Charles; Joseph Marie; Libermann Towia A; Treon Steven P; Munshi Nikhil C; Richardson Paul G; Hideshima Teru; Anderson Kenneth C
Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(22):14374-9.
-
2002: Akiyama Masaharu; Hideshima Teru; Munshi Nikhil C; Anderson Kenneth C
Telomerase inhibitors as anticancer therapy.
Current medicinal chemistry. Anti-cancer agents 2002;2(5):567-75.
-
2002: Gupta Deepak; Hideshima Teru; Anderson Kenneth C
Novel biologically based therapeutic strategies in myeloma.
Reviews in clinical and experimental hematology 2002;6(3):301-24.
-
2002: Lin Boris; Podar Klaus; Gupta Deepak; Tai Yu-Tzu; Li Sigui; Weller Edie; Hideshima Teru; Lentzsch Suzanne; Davies Faith; Li Cheng; Weisberg Ellen; Schlossman Robert L; Richardson Paul G; Griffin James D; Wood Jeanette; Munshi Nikhil C; Anderson Kenneth C
The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Cancer research 2002;62(17):5019-26.
-
2002: LeBlanc Richard; Catley Laurence P; Hideshima Teru; Lentzsch Suzanne; Mitsiades Constantine S; Mitsiades Nicholas; Neuberg Donna; Goloubeva Olga; Pien Christine S; Adams Julian; Gupta Deepak; Richardson Paul G; Munshi Nikhil C; Anderson Kenneth C
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
Cancer research 2002;62(17):4996-5000.
-
2002: Chauhan Dharminder; Catley Laurence; Hideshima Teru; Li Guilan; Leblanc Richard; Gupta Deepak; Sattler Martin; Richardson Paul; Schlossman Robert L; Podar Klaus; Weller Edie; Munshi Nikhil; Anderson Kenneth C
2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells.
Blood 2002;100(6):2187-94.
-
2002: Hayashi Toshiaki; Hideshima Teru; Akiyama Masaharu; Richardson Paul; Schlossman Robert L; Chauhan Dharminder; Munshi Nikhil C; Waxman Samuel; Anderson Kenneth C
Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.
Molecular cancer therapeutics 2002;1(10):851-60.
-
2002: Munshi Nikhil C; Hideshima Teru; Chauhan Dharminder; Richardson Paul; Anderson Kenneth C
Novel biologically based therapies for multiple myeloma.
International journal of hematology 2002;76 Suppl 1():340-1.
-
2002: Mitsiades Constantine S; Mitsiades Nicholas; Poulaki Vassiliki; Schlossman Robert; Akiyama Masaharu; Chauhan Dharminder; Hideshima Teru; Treon Steven P; Munshi Nikhil C; Richardson Paul G; Anderson Kenneth C
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Oncogene 2002;21(37):5673-83.
-
2002: Gupta Deepak; Podar Klaus; Tai Yu Tzu; Lin Boris; Hideshima Teru; Akiyama Masaharu; LeBlanc Richard; Catley Laurence; Mitsiades Nicholas; Mitsiades Constantine; Chauhan Dharminder; Munshi Nikhil C; Anderson Kenneth C
beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.
Experimental hematology 2002;30(7):711-20.
-
2002: Akiyama Masaharu; Hideshima Teru; Hayashi Toshiaki; Tai Yu-Tzu; Mitsiades Constantine S; Mitsiades Nicholas; Chauhan Dharminder; Richardson Paul; Munshi Nikhil C; Anderson Kenneth C
Cytokines modulate telomerase activity in a human multiple myeloma cell line.
Cancer research 2002;62(13):3876-82.
-
2002: Brander Christian; Raje Noopur; O'Connor Paula G; Davies Faith; Davis Jennifer; Chauhan Darminder; Hideshima Teru; Martin Jeff; Osmond Dennis; Kedes Dean H; Walker Bruce D; Scadden David T; Anderson Kenneth C
Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma.
Blood 2002;100(2):698-700.
-
2002: Mitsiades Nicholas; Mitsiades Constantine S; Poulaki Vassiliki; Chauhan Dharminder; Richardson Paul G; Hideshima Teru; Munshi Nikhil C; Treon Steven P; Anderson Kenneth C
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.
Blood 2002;99(12):4525-30.
-
2002: Mitsiades Nicholas; Mitsiades Constantine S; Poulaki Vassiliki; Chauhan Dharminder; Richardson Paul G; Hideshima Teru; Munshi Nikhil; Treon Steven P; Anderson Kenneth C
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.
Blood 2002;99(11):4079-86.
-
2002: Hideshima Teru; Chauhan Dharminder; Hayashi Toshiaki; Podar Klaus; Akiyama Masaharu; Gupta Deepak; Richardson Paul; Munshi Nikhil; Anderson Kenneth C
The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.
Molecular cancer therapeutics 2002;1(7):539-44.
-
2002: Richardson P; Hideshima T; Anderson K
Thalidomide in multiple myeloma.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2002;56(3):115-28.
-
2002: Hideshima Teru; Chauhan Dharminder; Richardson Paul; Mitsiades Constantine; Mitsiades Nicholas; Hayashi Toshiaki; Munshi Nikhil; Dang Lenny; Castro Alfredo; Palombella Vito; Adams Julian; Anderson Kenneth C
NF-kappa B as a therapeutic target in multiple myeloma.
The Journal of biological chemistry 2002;277(19):16639-47.
-
2002: Chauhan Dharminder; Auclair Daniel; Robinson Elisabeth K; Hideshima Teru; Li Guilan; Podar Klaus; Gupta Deepak; Richardson Paul; Schlossman Robert L; Krett Nancy; Chen Lan Bo; Munshi Nikhil C; Anderson Kenneth C
Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays.
Oncogene 2002;21(9):1346-58.
-
2002: Richardson Paul; Hideshima Teru; Anderson Kenneth
Thalidomide: emerging role in cancer medicine.
Annual review of medicine 2002;53():629-57.
-
2001: Gupta D; Treon S P; Shima Y; Hideshima T; Podar K; Tai Y T; Lin B; Lentzsch S; Davies F E; Chauhan D; Schlossman R L; Richardson P; Ralph P; Wu L; Payvandi F; Muller G; Stirling D I; Anderson K C
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(12):1950-61.
-
2001: Hideshima T; Chauhan D; Podar K; Schlossman R L; Richardson P; Anderson K C
Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
Seminars in oncology 2001;28(6):607-12.
-
2001: Hideshima T; Nakamura N; Chauhan D; Anderson K C
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma.
Oncogene 2001;20(42):5991-6000.
-
2001: Mitsiades C S; Treon S P; Mitsiades N; Shima Y; Richardson P; Schlossman R; Hideshima T; Anderson K C
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.
Blood 2001;98(3):795-804.
-
2001: Hideshima T; Chauhan D; Schlossman R; Richardson P; Anderson K C
The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.
Oncogene 2001;20(33):4519-27.
-
2001: Podar K; Tai Y T; Davies F E; Lentzsch S; Sattler M; Hideshima T; Lin B K; Gupta D; Shima Y; Chauhan D; Mitsiades C; Raje N; Richardson P; Anderson K C
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.
Blood 2001;98(2):428-35.
-
2001: Davies F E; Raje N; Hideshima T; Lentzsch S; Young G; Tai Y T; Lin B; Podar K; Gupta D; Chauhan D; Treon S P; Richardson P G; Schlossman R L; Morgan G J; Muller G W; Stirling D I; Anderson K C
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Blood 2001;98(1):210-6.
-
2001: Chauhan D; Hideshima T; Rosen S; Reed J C; Kharbanda S; Anderson K C
Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells.
The Journal of biological chemistry 2001;276(27):24453-6.
-
2001: Hideshima T; Richardson P; Chauhan D; Palombella V J; Elliott P J; Adams J; Anderson K C
The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.
Cancer research 2001;61(7):3071-6.
-
2000: Tai Y T; Teoh G; Lin B; Davies F E; Chauhan D; Treon S P; Raje N; Hideshima T; Shima Y; Podar K; Anderson K C
Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(11):6347-55.
-
2000: Treon S P; Maimonis P; Bua D; Young G; Raje N; Mollick J; Chauhan D; Tai Y T; Hideshima T; Shima Y; Hilgers J; von Mensdorff-Pouilly S; Belch A R; Pilarski L M; Anderson K C
Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma.
Blood 2000;96(9):3147-53.
-
2000: Hideshima T; Chauhan D; Shima Y; Raje N; Davies F E; Tai Y T; Treon S P; Lin B; Schlossman R L; Richardson P; Muller G; Stirling D I; Anderson K C
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Blood 2000;96(9):2943-50.
-
2000: Chauhan D; Pandey P; Hideshima T; Treon S; Raje N; Davies F E; Shima Y; Tai Y T; Rosen S; Avraham S; Kharbanda S; Anderson K C
SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells.
The Journal of biological chemistry 2000;275(36):27845-50.
-
2000: Raje N; Kica G; Chauhan D; Zhang Y; Teoh G; Treon S P; Hideshima T; Deng J H; Gao S J; Alsina M; Wally J; Davies F E; Tai Y T; Pinkus G S; Pinkus J L; Skinner M; Comenzo R L; Anderson K C
Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis.
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2000;7(2):126-32.
-
2000: Hideshima T; Chauhan D; Teoh G; Raje N; Treon S P; Tai Y T; Shima Y; Anderson K C
Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(3):1180-9.
-
2000: Tai Y T; Teoh G; Shima Y; Chauhan D; Treon S P; Raje N; Hideshima T; Davies F E; Anderson K C
Isolation and characterization of human multiple myeloma cell enriched populations.
Journal of immunological methods 2000;235(1-2):11-9.
-
2000: Teoh G; Tai Y T; Urashima M; Shirahama S; Matsuzaki M; Chauhan D; Treon S P; Raje N; Hideshima T; Shima Y; Anderson K C
CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines.
Blood 2000;95(3):1039-46.
-
1999: Chauhan D; Hideshima T; Pandey P; Treon S; Teoh G; Raje N; Rosen S; Krett N; Husson H; Avraham S; Kharbanda S; Anderson K C
RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells.
Oncogene 1999;18(48):6733-40.
-
1999: Chauhan D; Hideshima T; Treon S; Teoh G; Raje N; Yoshihimito S; Tai Y T; Li W; Fan J; DeCaprio J; Anderson K C
Functional interaction between retinoblastoma protein and stress-activated protein kinase in multiple myeloma cells.
Cancer research 1999;59(6):1192-5.
-
1999: Chauhan D; Bharti A; Raje N; Gustafson E; Pinkus G S; Pinkus J L; Teoh G; Hideshima T; Treon S P; Fingeroth J D; Anderson K C
Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells.
Blood 1999;93(5):1482-6.
Sign-in to see more
